tirzepatide phase 2 obesity for maintenance of bodyweight reduction in people with in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial Tirzepatide Was Associated with Improved

They are not approved to treat menopause symptoms and are not appropriate for everyone, but their mechanisms help reveal the biological links between metabolism, brain function, and the experiences many women report during this stage of life

Tirzepatide activates two receptors both GLP 1 and GIP (glucose dependent insulinotropic polypeptide)

A spokesperson for Eli Lilly, which makes the weight-loss drug Zepbound, told Scientific American in an e-mail, We do not have data to share concerning changes in food taste or preference among individuals taking GLP-1 medications. The spokesperson added that known side effects are listed on the medications labels and that anyone experiencing those side effects should contact their health care provider

LiuYJiangJJDuSYMuLSFanJJHuJCet al

However, animal studies indicate that they could be harmful to the developing fetus